Moving on, additional analysis for a possible association between CD33 rs3865444 and other outcomes (e.g., age at MS onset, response to treatments, multiple sclerosis severity score (MSSS) and expanded disability status scale (EDSS), annualized relapse rate (ARR), smoking behavior, etc.)could have given more robustness to our results. This evidence concerns the gene CD33 and myeloid sarcoma.